Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Deferoxamine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 595 records · Page 33Linked to original sources
PubMed1999

Inhibitory effects of deferoxamine on UVB-induced AP-1 transactivation.

Production of reactive oxygen species (ROS) by iron can contribute directly to DNA and protein damage and may contribute to cell signaling and proliferation. We have examined the effects of the iron(III) chelator deferroxamine (DFO) and iron (FeCl(3)) on UVB (290-320 nm)-induced activator protein 1 (AP-1) signaling. The ability of DFO to inhibit UVB-induced AP-1 transactivation was tested in a human keratinocyte cell line stably transfected with a luciferase reporter driven by a single AP-1 element. DFO treatment 24 h prior to UVB irradiation reduced UVB-induced AP-1 transactivation by approximately 80%, with the effect of DFO diminishing as pre-treatment time was shortened. Treatment with FeCl(3) a minimum of 6 h prior to UVB potentiated the UVB induction of AP-1 transactivation by 2-3-fold. DFO was able to ablate both the UVB induction of AP-1 transactivation as well as the potentiation by FeCl(3). The antioxidants Trolox and N-acetyl cysteine were both able to inhibit UVB-induced AP-1 transactivation and Trolox was able to inhibit the potentiation of UVB-induced AP-1 by FeCl(3). These results indicate that UVB-induced AP-1 activation may be in part due to oxidant effects of UVB and intercellular iron.

Antioxidants↗
PubMed1985

Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia.

Although the preliminary findings are encouraging, to assess the effectiveness of the SHYD program on the long-term course of thalassemia, a larger patient population and longer treatment and follow-up period are needed. The presence of cardiac abnormalities in patients in Group I suggests that to prevent heart damage in thalassemia, it may be necessary to start the HTP and effective chelation therapy at a very young age, realizing that the amount of iron removed will be small. The finding that two of the four patients who survived to receive the largest amount of Fe/kg have intact spleens and another had splenectomy at age 24 suggests that, in these patients, the spleen may have had a protective role for the heart. If this observation is confirmed, it would provide evidence that removal of the spleen may adversely affect the long-term course of patients with thalassemia. Six years' experience with the SHYD program has not provided evidence for significant acute or chronic toxicity. This suggests that it might be safe to administer the i.v. treatments at home, a program that is anticipated for the future, as it would significantly reduce cost and possibly be more convenient.

Adolescent↗